USA flag logo/image

An Official Website of the United States Government

Development of Antibodies for Drug Metabolizing Enzymes

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
22216
Program Year/Program:
1994 / SBIR
Agency Tracking Number:
22216
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
OXFORD BIOMEDICAL RESEARCH, INC.
2165 AVON INDUSTRIAL DRIVE ROCHESTER HILLS, MI 48309-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 1994
Title: Development of Antibodies for Drug Metabolizing Enzymes
Agency: HHS
Contract: N/A
Award Amount: $419,964.00
 

Abstract:

We will develop and market a comprehensive collection of antibodies specific for enzymes that play a significant role in drug metabolism . Availability of specific antibodies will greatly facilitate studies of polymorphisms, species and tissue distribution of drug metabolizing enzymes, and the role of individual enzymes in the metabolism of endogenous and xenobiotic chemicals. Widespread availability of specific antibodies will overcome current limitations. Some of these limitations include restricted access to antibodies, differences in specificity between preparations, and lack of specificity for many antibodies. We have already developed several goat antibodies directed against rabbit cytochromes P450; antibodies specific for prostaglandin H synthase, including anti-peptide antibodies specific for the recently discovered mitogen inducible PGHS-2, may exhibit a different spectrum of xenobiotic activation than PGHS-1. We are currently developing anti-peptide antibodies specific for mammalian lipoxygenases, which are also implicated in xenobiotic metabolism. However, we are well aware of the primary need for additional antibodies specific for P450 isoforms. We will therefore: (a) acquire available form-specific monoclonal and polyclonal antibodies by licensing form academic laboratories where possible, (b) to develop a series of anti-peptide antibodies and recombinant protein standards to the major P450 isoforms, and (c) to extensively characterize the specificity and reactivity of these antibodies in standard assays.

Principal Investigator:

Kim Hyesook
8106285104

Business Contact:

Small Business Information at Submission:

Oxford Biomedical Research,
P. O. Box 522, 1600 Hosner Roa Oxford, MI 48371

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No